Pharmaceutical companies fund the bulk of clinical research that is carried out on medications. Poor outcomes from these studies can have negative effects on sales of medicines. Previous research has shown that company funded research is much more likely to yield positive outcomes than research with any other sponsorship. The aim of this article is to investigate the possible ways in which bias can be introduced into research outcomes by drawing on concrete examples from the published literature. Poorer methodology in industry-funded research is not likely to account for the biases seen. Biases are introduced through a variety of measures including the choice of comparator agents, multiple publication of positive trials and non-publication of negative trials, reinterpreting data submitted to regulatory agencies, discordance between results and conclusions, conflict-of-interest leading to more positive conclusions, ghostwriting and the use of “seeding” trials. Thus far, efforts to contain bias have largely focused on more stringent rules regarding conflict-of-interest (COI) and clinical trial registries. There is no evidence that any measures that have been taken so far have stopped the biasing of clinical research and it’s not clear that they have even slowed down the process. Economic theory predicts that firms will try to bias the evidence base wherever its benefits exceed its costs. The examples given here confirm what theory predicts. What will be needed to curb and ultimately stop the bias that we have seen is a paradigm change in the way that we treat the relationship between pharmaceutical companies and the conduct and reporting of clinical trials.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
AMSA PharmFree Scorecard 2009. (2009). Executive summary updated. http://amsascorecard.org/executive-summary. Accessed 26 Sept 2010.
Andersen, M., Ktragstrup, J., & Søndergaard, J. (2006). How conducting a clinical trial affects physicians’ guideline adherence and drug preferences. JAMA, 295, 2759–2764.
Angell, M. (2004). The truth about the drug companies: How they deceive us and what to do about it. New York: Random House.
Austin, P. C., Mamdani, M. M., Tu, K., & Jaakkimainen, L. (2003). Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women’s Health Initiative Study. JAMA, 289, 3241–3242.
Baker, D. (2008). The benefits and savings from publicly funded clinical trials of prescription drugs. International Journal of Health Services, 38, 731–750.
Bell, C. M., Urbach, D. R., Ray, J. G., Bayoumi, A., Rosen, A. B., Greenberg, D., et al. (2006). Bias in published cost effectiveness studies: Systematic review. BMJ, 332, 699–703.
Bero, L., Oostvogel, F., Bacchetti, P., & Lee, K. (2007). Factors associated with findings of published trials of drug–drug comparisons: Why some statins appear more efficacious than others. PLoS Medicine, 4, e184.
Bero, L. A., & Rennie, D. (1996). Influences on the quality of published drug studies. International Journal of Technology Assessment in Health Care, 12, 209–237.
Campbell, E. G., Weissman, J. S., Ehringhaus, S., Rao, S. R., Moy, B., Feibelmann, S., et al. (2007). Institutional academic–industry relationships. JAMA, 298, 1779–1786.
Cooper, R. J., Gupta, M., Wilkes, M. S., & Hoffman, J. R. (2006). Conflict of interest disclosure policies and practices in peer-reviewed biomedical journals. Journal of General Internal Medicine, 21, 1248–1252.
Dembner, A. (2002). Report raps drug firms' 'post-approval studies. Boston Globe.
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010). Trends in risks associated with new drug development: Success rates for investigational drugs. Clinical Pharmacology and Therapeutics, 87, 272–277.
Djulbegovic, B., Cantor, A., & Clarke, M. (2003). The importance of preservation of the ethical principle of equipoise in the design of clinical trials: Relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Accountability in Research, 10, 301–315.
Drazen, J. M., de Leeuw, P. W., Laine, C., Mulrow, C., DeAngelis, C. D., Frizelle, F. A., et al. (2010). Toward more uniform conflict disclosures—the updated ICJME conflict of interest reporting forms. New England Journal of Medicine, 363, 188–189.
Dunbar, C. E., & Tallman, M. S. (2009). ‘Ghostbusting’ at blood. Blood, 113, 502–503.
Finkelstein, S., & Temin, P. (2008). Reasonable Rx: Solving the drug price crisis. Upper Saddle River: FT Press.
Franco, O. H., Peeters, A., Looman, C. W. N., & Bonneux, L. (2005). Cost effectiveness of statins in coronary heart disease. Journal of Epidemiology and Community Health, 59, 927–933.
Friedman, L. S., & Richter, E. D. (2004). Relationship between conflicts of interest and research results. Journal of General Internal Medicine, 19, 51–56.
Fries, J. F., & Krishnan, E. (2004). Equipoise, design bias, and randomized controlled trials: The elusive ethics of new drug development. Arthritis Research and Therapy, 6, R250–R255.
Fugh-Berman, A. (2005). The corporate coauthor. Journal of General Internal Medicine, 20, 546–548.
Fugh-Berman, A. (2010). The haunting of medical journals: How ghostwriting sold “HRT”. PLoS Medicine, 7(9), e1000335.
Goozner, M. (2004). Unrevealed: Non-disclosure of conflicts of interest in four medical and scientific journals. Washington, DC: Center for Science in the Public Interest.
Gøtzsche, P. C. (1989). Multiple publication of reports of drug trials. European Journal of Clinical Pharmacology, 36, 429–432.
Hartmann, M., Knoth, H., Schulz, D., & Knoth, S. (2003). Industry-sponsored economic studies in oncology vs. studies sponsored by nonprofit organisations. British Journal of Cancer, 89, 1405–1408.
Healy, D., & Cattell, D. (2003). Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry, 183, 22–27.
Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006). Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry, 163, 185–194.
Hersh, A. L., Stefanick, M. L., & Stafford, R. S. (2004). National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA, 291, 47–53.
Hill, K. P., Ross, J. S., Egilman, D. S., & Krumholz, H. M. (2008). The ADVANTAGE seeding trial: A review of internal documents. Annals of Internal Medicine, 149, 251–258.
Hirsch, L. J. (2009). Conflicts of interest, authorship, and disclosures in industry-related scientific publications: The tort bar and editorial oversight of medical journals. Mayo Clinic Proceedings, 84, 811–821.
Hole, O. P., Winther, F. Ø., & Straume, B. (2001). Clinical research: The influence of the pharmaceutical industry. European Journal of Clinical Pharmacology, 56, 851–853.
Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 280, 605–613.
Huston, P., & Moher, D. (1996). Redundancy, disaggregation, and the integrity of medical research. Lancet, 347, 1024–1026.
Jagsi, R., Sheets, N., Jankovic, A., Motomura, A. R., Amarnath, S., & Ubel, P. A. (2009). Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. Cancer, 115, 2783–2791.
Johansen, H. K., & Gotzsche, P. C. (1999). Problems in the design and reporting of trials of antifungal agents encountered during meta-analyses. JAMA, 282, 1752–1759.
Jørgensen, A. W., Maric, K. L., Tendal, B., Faurschou, A., & Gøtzsche, P. C. (2008). Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions. BMC Medical Research Methodology, 8, 60.
Katz, D., Caplan, A. L., & Merz, J. F. (2003). All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift-giving. American Journal of Bioethics, 3, 39–46.
Kjaergard, L. L., & Als-Nielsen, B. (2002). Association between competing interests and authors’ conclusions: Epidemiological study of randomised clinical trials published in the BMJ. BMJ, 325, 249.
Lacasse, J. R., & Leo, J. (2010). Ghostwriting at elite academic medical centers in the United States. PLoS Medicine, 7, e1000230.
Lewis, T., Reichman, J., & So, A. (2007). The case for public funding and public oversight of clinical trials. Economists’ Voice, 4(1), 1–4.
Lexchin, J., Bero, L., Djubegovic, B., & Clark, O. (2003). Pharmaceutical industry sponsored research: Evidence for a systematic bias. BMJ, 326, 1167–1170.
Lexchin, J., Sekeres, M., Gold, J., Ferris, L. E., Kalkar, S. R., Wu, W., et al. (2008). National evaluation of policies on individual financial conflicts of interest in Canadian academic health science centers. Journal of General Internal Medicine, 23, 1896–1903.
Light, D. W. (2006). Basic research funds to discover important new drugs: Who contributes how much? In M. A. Burke & A. de Francisco (Eds.), Monitoring financial flows for health research 2005: Behind the global numbers (pp. 29–43). Geneva: Global Fund for Health Research.
Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003). Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. BMJ, 326, 1171–1173.
Miners, A. H., Garau, M., Fidan, D., & Fischer, A. J. (2005). Comparing estimates of cost effectiveness submitted to the National Institute for Cliinical Excellence (NICE) by different organisations: retrospective study. BMJ, 330, 65–69.
Montgomery, J. H., Byerly, M., Carmody, T., Li, B., Miller, D. R., Varghese, F., et al. (2004). An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials, 25, 598–612.
Moses, H. I., Dorsey, E. R., Matheson, D. H. M., & Thier, S. O. (2005). Financial anatomy of biomedical research. JAMA, 294, 1333–1342.
Nieto, A., Mazon, A., Pamies, R., Linana, J. J., Lanuza, A., Jiménez, F. O., et al. (2007). Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Archives of Internal Medicine, 167, 2047–2053.
Ninan, P. T., Poole, R. M., & Stiles, G. L. (2008). Selective publication of antidepressant trials. New England Journal of Medicine, 358, 2180.
Patsopoulos, N. A., Ioannidis, J. P. A., & Analatos, A. A. (2006). Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ, 332, 1061–1064.
Perlis, C. S., Harwood, M., & Perlis, R. H. (2005a). Extent and impact of industry sponsorship conflicts of interest in dermatology research. Journal of the American Academy of Dermatology, 52, 967–971.
Perlis, R. H., Perlis, C. S., Wu, Y., Hwang, C., Joseph, M., & Nierenberg, A. A. (2005b). Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. American Journal of Psychiatry, 162, 1957–1960.
Psaty, B. M., & Rennie, D. (2006). Clinical trial investigators and their prescribing patterns: Another dimension to the relationship between physician investigators and the pharmaceutical industry. JAMA, 295, 2787–2789.
Rasmussen, M., Lee, K., & Bero, L. (2009). Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials, 10, 116.
Rising, K., Bacchetti, P., & Bero, L. (2008). Reporting bias in drug trials submitted to the Food and Drug Administration: Review of publication and presentation. PLoS Medicine, 5, e217.
Rochon, P. A., Gurwitz, J. H., Simms, R. W., Fortin, P. R., Felson, D. T., Minaker, K. L., et al. (1994). A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine, 154, 157–163.
Rochon, P. A., Sekeres, M., Lexchin, J., Moher, D., Wu, W., Kalkar, S. R., et al. (2010). Institutional financial conflicts of interest policies at Canadian academic health science centres: A national survey. Open Medicine, 4, E134–E138.
Ross, J. S., Hill, K. P., Egilman, D. S., & Krumholz, H. M. (2008). Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib ligitation. JAMA, 299, 1800–1812.
Safer, D. J. (2002). Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. Journal of Nervous and Mental Disease, 190, 583–592.
Schafer, A. (2004). Biomedical conflicts of interest: A defence of the sequestration thesis—learning from the cases of Nancy Olivieri and David Healy. Journal of Medical Ethics, 30, 8–24.
Sekeres, M., Gold, J. L., Chan, A.-W., Lexchin, J., Moher, D., Van Laethem, M. L. P., et al. (2008). Poor reporting of scientific leadership information in clinical trial registers. PLoS One, 3, e1610.
Sismondo, S. (2008a). How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science and Medicine, 66, 1909–1914.
Sismondo, S. (2008b). Pharmaceutical company funding and its consequences: A qualitative systematic review. Contemporary Clinical Trials, 29, 109–113.
Spielmans, G. I., Biehn, T. L., & Sawrey, D. L. (2010). A case study of salami slicing: Pooled analyses of duloxetine for depression. Psychotherapy and Psychosomatics, 79, 97–106.
Stossel, T. P. (2005). Regulating academic–industrial research relationships—solving problems or stifling progress? New England Journal of Medicine, 353, 1060–1065.
Tramèr, M. R., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (1997). Impact of covert duplicate publication on meta-analysis: A case study. BMJ, 315, 635–640.
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358, 252–260.
van McCrary, S., Anderson, C. B., Jakovljevic, J., Khan, T., McCullough, L. B., Wray, N. P., et al. (2000). A national survey of policies on disclosure of conflicts of interest in biomedical research. New England Journal of Medicine, 343, 1621–1626.
Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet, 363, 1341–1345.
Wood, A. J. J. (2009). Progress and deficiencies in the registration of clinical trials. New England Journal of Medicine, 360, 824–830.
Writing Group for the Women’s Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288, 321–333.
Wyatt, J. (1991). Use and sources of medical knowledge. Lancet, 338, 1368–1373.
Yank, V., Rennie, D., & Bero, L. A. (2007). Financial ties and concordance between results and conclusions in meta-analyses: Retrospective cohort study. BMJ, 335, 1202–1205.
Zarin, D. A., Tse, T., & Ide, N. C. (2005). Trial registration at ClinicalTrials.gov between May and October 2005. New England Journal of Medicine, 353, 2779–2787.
About this article
Cite this article
Lexchin, J. Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. Sci Eng Ethics 18, 247–261 (2012). https://doi.org/10.1007/s11948-011-9265-3
- Clinical trials
- Pharmaceutical industry